Antimicrobial Strategies for Cystic Fibrosis


Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.

Original languageEnglish
JournalSeminars in respiratory and critical care medicine
Issue number2
Pages (from-to)297-306
Number of pages10
Publication statusPublished - Apr 2023


  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • nontuberculous mycobacteria
  • evidence
  • eradication
  • inhaled antibiotics


Dive into the research topics of 'Antimicrobial Strategies for Cystic Fibrosis'. Together they form a unique fingerprint.

Cite this